2023
Cost‐Effectiveness of Weight‐Loss Interventions Prior to Total Knee Replacement for Patients With Class III Obesity
Kostic AM, Leifer VP, Selzer F, Hunter DJ, Paltiel AD, Chen AF, Robinson MK, Neogi T, Collins JE, Messier SP, Edwards RR, Katz JN, Losina E. Cost‐Effectiveness of Weight‐Loss Interventions Prior to Total Knee Replacement for Patients With Class III Obesity. Arthritis Care & Research 2023, 75: 1752-1763. PMID: 36250415, PMCID: PMC10375659, DOI: 10.1002/acr.25044.Peer-Reviewed Original ResearchMeSH KeywordsArthroplasty, Replacement, KneeCost-Benefit AnalysisGastrectomyGastric BypassHumansObesityObesity, MorbidOsteoarthritis, KneeWeight LossConceptsLaparoscopic sleeve gastrectomyClass III obesityIncremental cost-effectiveness ratioTotal knee replacementQuality-adjusted life expectancyWeight loss interventionProbabilistic sensitivity analysesKnee replacementNonsurgical weight loss interventionsLong-term clinical benefitWeight lossKnee osteoarthritis patientsWeight loss strategiesHealth care sector perspectiveOsteoarthritis Policy ModelLifetime medical costsCost-effectiveness ratioWeight loss/Gastric bypassSleeve gastrectomyPrimary outcomeLoss interventionOsteoarthritis patientsClinical benefitHigher complications
2022
Does gabapentin provide benefit for patients with knee OA? A benefit-harm and cost-effectiveness analysis
Bensen G, Rogers A, Leifer V, Edwards R, Neogi T, Kostic A, Paltiel A, Collins J, Hunter D, Katz J, Losina E. Does gabapentin provide benefit for patients with knee OA? A benefit-harm and cost-effectiveness analysis. Osteoarthritis And Cartilage 2022, 31: 279-290. PMID: 36414225, PMCID: PMC9892279, DOI: 10.1016/j.joca.2022.07.013.Peer-Reviewed Original ResearchMeSH KeywordsCost-Benefit AnalysisCost-Effectiveness AnalysisGabapentinHumansNeuralgiaOsteoarthritis, KneeQuality-Adjusted Life YearsConceptsQuality-adjusted life yearsIncremental cost-effectiveness ratioKnee osteoarthritisUsual careNociplastic painCumulative quality-adjusted life yearsMore quality-adjusted life yearsNeuropathic pain syndromesDirect medical costsOsteoarthritis Policy ModelLifetime direct medical costsCost-effectiveness ratioCost-effectiveness analysisOA carePainDETECT questionnairePain syndromeSocietal Cost of Opioid Use in Symptomatic Knee Osteoarthritis Patients in the United States
Huizinga JL, Stanley EE, Sullivan JK, Song S, Hunter DJ, Paltiel AD, Neogi T, Edwards RR, Katz JN, Losina E. Societal Cost of Opioid Use in Symptomatic Knee Osteoarthritis Patients in the United States. Arthritis Care & Research 2022, 74: 1349-1358. PMID: 33629485, PMCID: PMC8382774, DOI: 10.1002/acr.24581.Peer-Reviewed Original ResearchConceptsSymptomatic knee osteoarthritisOpioid use disorderOpioid useMcMaster Universities Osteoarthritis Index (WOMAC) pain scoreSymptomatic knee osteoarthritis patientsLong-term pain managementProlonged opioid usePublic health causeStrong opioid useSocietal costsKnee osteoarthritis patientsSocietal economic burdenDirect medical costsMedicare Current Beneficiary SurveyOsteoarthritis Policy ModelCriminal justice costsOUD prevalencePain scoresSD ageOpioid regimensPain managementKnee osteoarthritisOsteoarthritis patientsWestern OntarioMedical costs
2021
The Value of Total Knee Replacement in Patients With Knee Osteoarthritis and a Body Mass Index of 40 kg/m2 or Greater : A Cost-Effectiveness Analysis.
Chen AT, Bronsther CI, Stanley EE, Paltiel AD, Sullivan JK, Collins JE, Neogi T, Katz JN, Losina E. The Value of Total Knee Replacement in Patients With Knee Osteoarthritis and a Body Mass Index of 40 kg/m2 or Greater : A Cost-Effectiveness Analysis. Annals Of Internal Medicine 2021, 174: 747-757. PMID: 33750190, PMCID: PMC8288249, DOI: 10.7326/m20-4722.Peer-Reviewed Original ResearchConceptsIncremental cost-effectiveness ratioBody mass indexTotal knee replacementKnee replacementCost-effectiveness analysisTKR recipientsKnee osteoarthritisMass indexEnd-stage knee osteoarthritisLong-term clinical benefitCost-effective strategyPreoperative pain levelNational InstituteOsteoarthritis Policy ModelLifetime medical costsCost-effectiveness ratioBase-case analysisProbabilistic sensitivity analysesMultiple comorbiditiesCost-effectiveness perspectivePain levelsComplication rateClinical benefitCardiovascular diseaseMedical costs
2019
Cost‐Effectiveness of Diet and Exercise for Overweight and Obese Patients With Knee Osteoarthritis
Losina E, Smith KC, Paltiel AD, Collins JE, Suter LG, Hunter DJ, Katz JN, Messier SP. Cost‐Effectiveness of Diet and Exercise for Overweight and Obese Patients With Knee Osteoarthritis. Arthritis Care & Research 2019, 71: 855-864. PMID: 30055077, PMCID: PMC6349519, DOI: 10.1002/acr.23716.Peer-Reviewed Original ResearchMeSH KeywordsAgedCaloric RestrictionComparative Effectiveness ResearchComputer SimulationCost-Benefit AnalysisExerciseFemaleHealth Care CostsHealthy LifestyleHumansMaleMiddle AgedModels, EconomicMonte Carlo MethodObesityOsteoarthritis, KneeQuality of LifeQuality-Adjusted Life YearsRisk Reduction BehaviorTime FactorsTreatment OutcomeWeight LossConceptsIncremental cost-effectiveness ratioProbabilistic sensitivity analysesKnee osteoarthritisObese patientsIntensive dietSocietal perspectiveHealth care sector perspectiveLifetime costsOsteoarthritis Policy ModelCost-effectiveness ratioIDEA trialPain reductionUsual careExercise programArthritis trialsTreatment strategiesLifetime horizonClinical practicePatientsOsteoarthritisOverweightQALYHealth care sectorWeight reductionDiet
2018
Cost-effectiveness of health coaching and financial incentives to promote physical activity after total knee replacement
Smith KC, Paltiel AD, Yang HY, Collins JE, Katz JN, Losina E. Cost-effectiveness of health coaching and financial incentives to promote physical activity after total knee replacement. Osteoarthritis And Cartilage 2018, 26: 1495-1505. PMID: 30092263, PMCID: PMC6202236, DOI: 10.1016/j.joca.2018.07.014.Peer-Reviewed Original ResearchConceptsIncremental cost-effectiveness ratioProbabilistic sensitivity analysesFinancial incentivesOne-way sensitivity analysesDeterministic sensitivity analysesCost-effectiveness ratioSensitivity analysisCost-effectiveness outcomesOsteoarthritis Policy ModelEfficacy of THCKnee replacement recipientsPolicy modelLife yearsTelephonic health coachingQALYHealthcare perspectiveCost-effectiveness of generic celecoxib in knee osteoarthritis for average-risk patients: a model-based evaluation
Losina E, Usiskin I, Smith S, Sullivan J, Smith K, Hunter D, Messier S, Paltiel A, Katz J. Cost-effectiveness of generic celecoxib in knee osteoarthritis for average-risk patients: a model-based evaluation. Osteoarthritis And Cartilage 2018, 26: 641-650. PMID: 29481917, PMCID: PMC6334297, DOI: 10.1016/j.joca.2018.02.898.Peer-Reviewed Original Research
2016
Cost‐Effectiveness of Tramadol and Oxycodone in the Treatment of Knee Osteoarthritis
Smith SR, Katz JN, Collins JE, Solomon DH, Jordan JM, Suter LG, Yelin EH, Paltiel AD, Losina E. Cost‐Effectiveness of Tramadol and Oxycodone in the Treatment of Knee Osteoarthritis. Arthritis Care & Research 2016, 69: 234-242. PMID: 27111538, PMCID: PMC5378156, DOI: 10.1002/acr.22916.Peer-Reviewed Original ResearchMeSH KeywordsAgedAged, 80 and overAnalgesics, OpioidComputer SimulationCost-Benefit AnalysisFemaleHumansMaleMiddle AgedOsteoarthritis, KneeOxycodoneTramadolConceptsIncremental cost-effectiveness ratioQuality-adjusted life yearsOA patientsTKA outcomesKnee OA patientsKnee osteoarthritis treatmentInfluence of opioidsOsteoarthritis Policy ModelCost-effectiveness ratioConservative treatmentPain reductionPain reliefPersistent painKnee osteoarthritisMean ageTKA utilizationTreatment optionsOsteoarthritis treatmentLife yearsOxycodoneTramadolTKALifetime costsOpioidsOutcomes
2015
Model-based evaluation of cost-effectiveness of nerve growth factor inhibitors in knee osteoarthritis: impact of drug cost, toxicity, and means of administration
Losina E, Michl G, Collins JE, Hunter DJ, Jordan JM, Yelin E, Paltiel AD, Katz JN. Model-based evaluation of cost-effectiveness of nerve growth factor inhibitors in knee osteoarthritis: impact of drug cost, toxicity, and means of administration. Osteoarthritis And Cartilage 2015, 24: 776-785. PMID: 26746146, PMCID: PMC4838505, DOI: 10.1016/j.joca.2015.12.011.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAged, 80 and overAntibodies, Monoclonal, HumanizedAnti-Inflammatory Agents, Non-SteroidalCost-Benefit AnalysisDisease ProgressionDrug CostsFemaleHealth Care CostsHealth Services ResearchHumansInfusions, IntravenousInjections, SubcutaneousMaleMiddle AgedModels, EconometricNerve Growth FactorOsteoarthritis, KneePain MeasurementQuality-Adjusted Life YearsSelf AdministrationUnited StatesConceptsNerve growth factor inhibitorsQuality-adjusted life yearsStandard of careTotal knee replacement surgeryIncremental cost-effectiveness ratioGrowth factor inhibitorsKnee osteoarthritisFactor inhibitorsOA progressionSelf-administered subcutaneous injectionsSevere knee osteoarthritisDirect medical costsKnee replacement surgeryQuality-adjusted life expectancyOsteoarthritis Policy ModelCost-effectiveness ratioMeans of administrationBase-case analysisCost-effective treatmentHospital deliveryIntravenous infusionDisease progressionLifetime riskReplacement surgerySubcutaneous injectionCost-effectiveness of nonsteroidal anti-inflammatory drugs and opioids in the treatment of knee osteoarthritis in older patients with multiple comorbidities
Katz JN, Smith SR, Collins JE, Solomon DH, Jordan JM, Hunter DJ, Suter LG, Yelin E, Paltiel AD, Losina E. Cost-effectiveness of nonsteroidal anti-inflammatory drugs and opioids in the treatment of knee osteoarthritis in older patients with multiple comorbidities. Osteoarthritis And Cartilage 2015, 24: 409-418. PMID: 26525846, PMCID: PMC4761310, DOI: 10.1016/j.joca.2015.10.006.Peer-Reviewed Original ResearchAgedAged, 80 and overAnalgesics, OpioidAnti-Inflammatory Agents, Non-SteroidalCelecoxibComorbidityCost-Benefit AnalysisDrug CostsDrug Therapy, CombinationFemaleHealth Services ResearchHumansIbuprofenMaleMiddle AgedNaproxenNonprescription DrugsOsteoarthritis, KneePainPain MeasurementProton Pump InhibitorsQuality-Adjusted Life YearsSensitivity and SpecificityTramadolTreatment OutcomeUnited StatesDefining the Value of Future Research to Identify the Preferred Treatment of Meniscal Tear in the Presence of Knee Osteoarthritis
Losina E, Dervan EE, Paltiel AD, Dong Y, Wright RJ, Spindler KP, Mandl LA, Jones MH, Marx RG, Safran-Norton CE, Katz JN. Defining the Value of Future Research to Identify the Preferred Treatment of Meniscal Tear in the Presence of Knee Osteoarthritis. PLOS ONE 2015, 10: e0130256. PMID: 26086246, PMCID: PMC4472814, DOI: 10.1371/journal.pone.0130256.Peer-Reviewed Original ResearchLifetime Medical Costs of Knee Osteoarthritis Management in the United States: Impact of Extending Indications for Total Knee Arthroplasty
Losina E, Paltiel AD, Weinstein AM, Yelin E, Hunter DJ, Chen SP, Klara K, Suter LG, Solomon DH, Burbine SA, Walensky RP, Katz JN. Lifetime Medical Costs of Knee Osteoarthritis Management in the United States: Impact of Extending Indications for Total Knee Arthroplasty. Arthritis Care & Research 2015, 67: 203-215. PMID: 25048053, PMCID: PMC4422214, DOI: 10.1002/acr.22412.Peer-Reviewed Original ResearchConceptsTotal knee arthroplastyDirect medical costsOA patientsKnee osteoarthritisMedical costsKnee arthroplastyTKA utilizationEligibility criteriaEffective nonoperative therapiesKellgren/LawrenceKnee osteoarthritis managementKnee OA patientsSymptomatic knee osteoarthritisMulticenter Osteoarthritis StudyLifetime costsUtilization Project dataOsteoarthritis Policy ModelLifetime direct medical costsLifetime medical costsHealth care costsMedicare reimbursement schedulesTotal lifetime costsNonoperative therapySymptomatic osteoarthritisOsteoarthritis management
2013
Placing a Price on Medical Device Innovation: The Example of Total Knee Arthroplasty
Suter LG, Paltiel AD, Rome BN, Solomon DH, Thornhill TS, Abrams SK, Katz JN, Losina E. Placing a Price on Medical Device Innovation: The Example of Total Knee Arthroplasty. PLOS ONE 2013, 8: e62709. PMID: 23671626, PMCID: PMC3646021, DOI: 10.1371/journal.pone.0062709.Peer-Reviewed Original ResearchDisease-modifying drugs for knee osteoarthritis: can they be cost-effective?
Losina E, Daigle ME, Suter LG, Hunter DJ, Solomon DH, Walensky RP, Jordan JM, Burbine SA, Paltiel AD, Katz JN. Disease-modifying drugs for knee osteoarthritis: can they be cost-effective? Osteoarthritis And Cartilage 2013, 21: 655-667. PMID: 23380251, PMCID: PMC3670115, DOI: 10.1016/j.joca.2013.01.016.Peer-Reviewed Original ResearchConceptsIncremental cost-effectiveness ratioQuality-adjusted life yearsTotal knee replacementPain reliefMajor toxicityRevision total knee replacementCare sequenceConservative pain managementGuideline-concordant careKnee OA treatmentQuality-adjusted life expectancyOsteoarthritis Policy ModelCost-effectiveness ratioCorticosteroid injectionKnee OAKnee osteoarthritisPain managementOsteoarthritis drugsKnee replacementDMOADsOA treatmentLife yearsProgressionLife expectancyRelief
2011
Impact of obesity and knee osteoarthritis on morbidity and mortality in older Americans.
Losina E, Walensky RP, Reichmann WM, Holt HL, Gerlovin H, Solomon DH, Jordan JM, Hunter DJ, Suter LG, Weinstein AM, Paltiel AD, Katz JN. Impact of obesity and knee osteoarthritis on morbidity and mortality in older Americans. Annals Of Internal Medicine 2011, 154: 217-26. PMID: 21320937, PMCID: PMC3260464, DOI: 10.7326/0003-4819-154-4-201102150-00001.Peer-Reviewed Original Research
2009
Medical decision making in patients with knee pain, meniscal tear, and osteoarthritis
Suter LG, Fraenkel L, Losina E, Katz JN, Gomoll AH, Paltiel AD. Medical decision making in patients with knee pain, meniscal tear, and osteoarthritis. Arthritis & Rheumatism 2009, 61: 1531-1538. PMID: 19877094, PMCID: PMC2804854, DOI: 10.1002/art.24893.Peer-Reviewed Original ResearchConceptsArthroscopic partial meniscectomyMeniscal tearsKnee painInternational Knee Documentation Committee scoreMagnetic resonance imaging (MRI) indicatorsObtainable clinical informationDegenerative meniscal tearsIndividuals ages 45Mean incremental gainIKDC scoreNonoperative managementAge 45Preoperative informationPartial meniscectomyClinical informationOsteoarthritisPainTearsLower likelihoodHigher likelihoodAlternative thresholdsMedical decisionsScoresIncremental gainPatientsCost-effectiveness of Total Knee Arthroplasty in the United States: Patient Risk and Hospital Volume
Losina E, Walensky RP, Kessler CL, Emrani PS, Reichmann WM, Wright EA, Holt HL, Solomon DH, Yelin E, Paltiel AD, Katz JN. Cost-effectiveness of Total Knee Arthroplasty in the United States: Patient Risk and Hospital Volume. JAMA Internal Medicine 2009, 169: 1113-1121. PMID: 19546411, PMCID: PMC2731300, DOI: 10.1001/archinternmed.2009.136.Peer-Reviewed Original ResearchMeSH KeywordsArthroplasty, Replacement, KneeCost-Benefit AnalysisHospital Bed CapacityHospitalsHumansOsteoarthritis, KneeRisk FactorsUnited States